COVID-19 and coagulopathy

Clin Respir J. 2021 Dec;15(12):1259-1274. doi: 10.1111/crj.13438. Epub 2021 Aug 30.

Abstract

The SARS-CoV-2 is a new coronavirus responsible for the COVID-19 disease and has caused the pandemic worldwide. A large number of cases have overwhelmed the healthcare system worldwide. The COVID-19 infection has been associated with a heightened risk of thromboembolic complications. Various mechanisms are leading to the high thrombotic risk in COVID-19 patients such as inflammation, endotheliitis, hyperviscosity, and hypercoagulability. We searched PubMed, EMBASE, and CINAHL from January 2020 to December 2020. We used the following search terms: COVID-19, coagulopathy, and thrombosis. We reviewed the epidemiology, clinical features, mechanisms, and treatment of COVID-19-associated coagulopathy.

Keywords: COVID-19; endotheliitis; heparin; microthrombosis; thrombosis.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Humans
  • Pandemics
  • SARS-CoV-2
  • Thromboembolism*
  • Thrombophilia* / complications
  • Thrombophilia* / epidemiology